TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00835939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% Dextrose and 1% Lidocaine
Description: Up to 3 injections provided to neovessels outside of the tendon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Up to 3 injections provided to neovessels outside of the tendon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sclerotherapy
Study: NCT03965728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1830839
Description: Tablet, oral.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
Study: NCT03558620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mask ventilation
Description: mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mask ventilation
Description: mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mask ventilation
Description: mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mask ventilation
Description: mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mask ventilation
Description: mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mask ventilation
Description: mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
Study: NCT00256529

Intervention type: PROCEDURE
Intervention: EGD with biopsies
Description: All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
Study: NCT02568709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT01906424

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
Study: NCT01790113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Univers™
Description: Control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse™ Total Shoulder Replacement
Description: Investigational
Study: NCT00920114

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT01927614

Intervention type: RADIATION
Intervention: Cardiac CT
Description: A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus.

Intervention type: RADIATION
Intervention: Cardiac CT
Description: A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus.
Study: NCT02012166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 10 mg
Description: MK-0893 10 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 40 mg
Description: MK-0893 40 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 40 mg
Description: MK-0893 40 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 40 mg
Description: MK-0893 40 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 200 mg
Description: MK-0893 200 mg administered orally in 240 mL of water
Study: NCT04170062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
Study: NCT02012166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 200 mg
Description: MK-0893 200 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 200 mg
Description: MK-0893 200 mg administered orally in 240 mL of water
Study: NCT04170062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
Study: NCT03505190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7062931
Description: RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7062931
Description: RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (SC).
Study: NCT00581100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period.
Study: NCT03468998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Grafting with small particle allograft
Description: Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Grafting with large particle allograft
Description: Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral ridge augmentation with small particle allograft
Description: Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral ridge augmentation with large particle allograft
Description: Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
Study: NCT03906409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant
Description: Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus
Description: Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
Study: NCT02399228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% EISO mouth rinse
Description: A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
Study: NCT02798757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Urine samples will be collected for 1HNMR spectroscopies
Study: NCT03512730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium brush
Description: a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic decontamination
Description: Classic decontamination will be performed by means of H2O2 3% and plastic curettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic decontamination
Description: Classic decontamination will be performed by means of H2O2 3% and plastic curettes
Study: NCT02743741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177 Octreotate
Description: Radiopharmaceutical
Study: NCT02552264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy for the Workplace
Description: Acceptance and Commitment Therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acceptance and Commitment Therapy for the Workplace
Description: Acceptance and Commitment Therapy
Study: NCT01688804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce sedentary time delivered via mobile smartphone
Description: The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
Study: NCT05299190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga intervention plus TAU
Description: The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Monitoring plus TAU
Description: clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
Study: NCT00830531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline as Placebo
Description: Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
Study: NCT03440411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg/daily as oral administration (PO) on days 1-21.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: 4 mg/daily as oral administration (PO) on days 1-21.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: 4 mg/daily as oral administration (PO) on days 1-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg/daily as oral administration (PO) on days 1-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg every other day as oral administration (PO) on days 1-28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 50 mg every other day as oral administration (PO) on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg as oral administration (PO) on days 1, 8, 15, 22.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg as oral administration (PO) on days 1, 8, 15, 22.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg as oral administration (PO) on days 1, 8, 15, 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg as oral administration (PO) on days 1, 8, 15, 22.
Study: NCT01900184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains magnesium stearate, silica dental type, anhydrous lactose
Study: NCT04070703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Go for Exercise & Healthy Aging Project
Description: Exercise and Cognition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Go for Exercise & Healthy Aging Project
Description: Exercise and Cognition

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: The Go for Exercise & Healthy Aging Project
Description: Exercise and Cognition
Study: NCT01568879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gout Disease Management Program
Description: The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
Study: NCT04408612

Intervention type: DIAGNOSTIC_TEST
Intervention: Scales for assessment of symptoms
Description: Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale.
Study: NCT03505190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (SC).
Study: NCT01589978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Plus Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
Study: NCT04170062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Delivery of Oxygen Therapy
Description: They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
Study: NCT01061515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT02012166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.